Albumin-Bound Paclitaxel
Showing 1 - 25 of 4,227
Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and
Recruiting
- Ovarian Carcinoma
- +6 more
- Albumin-bound paclitaxel and bevacizumab
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Breast Cancer Trial in Beijing (doxorubicin, epirubicin, pirarubicin)
Not yet recruiting
- Breast Cancer
- doxorubicin
- +6 more
-
Beijing, Beijing, ChinaCancer Hospital, ChineseAMS
Mar 17, 2022
Ovarian Cancer Trial (albumin-bound paclitaxel, paclitaxel)
Not yet recruiting
- Ovarian Cancer
- albumin-bound paclitaxel
- paclitaxel
- (no location specified)
Mar 31, 2022
Locally Advanced Pancreatic Cancer Trial in Shanghai (Tumor treating fields combined with Gemcitabine HCl and albumin binding
Not yet recruiting
- Locally Advanced Pancreatic Cancer
- Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
- Gemcitabine hydrochloride and albumin binding paclitaxel
-
Shanghai, Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
Dec 8, 2022
Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)
Not yet recruiting
- Breast Cancer
- Inetetamab
- +2 more
-
Beijing, ChinaCancer Hospital Chinese Academy Of Medical Sciences
Mar 14, 2022
Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)
Active, not recruiting
- Advanced Urothelial Carcinoma
- anti-PD-L1 antibody
- albumin bound paclitaxel
-
Beijing, Beijing, ChinaBeijing Tumor Hospital
Jan 20, 2022
Triple-negative Breast Cancer Trial in Bengbu (Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab)
Recruiting
- Triple-negative Breast Cancer
- Albumin-Bound Paclitaxel
- +2 more
-
Bengbu, Anhui, ChinaDepartment of Medical Oncology, First Affiliated Hospital of Ben
Mar 15, 2022
Soft Tissue Sarcoma Trial in Zhengzhou (Albumin-Bound Paclitaxel, Camrelizumab)
Recruiting
- Soft Tissue Sarcoma
- Albumin-Bound Paclitaxel
- Camrelizumab
-
Zhengzhou, Henan, ChinaDepartment of Bone and Soft Tissue, Henan Cancer Hospital
Jan 13, 2022
Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)
Not yet recruiting
- Solid Tumor, Adult
- EOC202
- albumin-bound paclitaxel
- (no location specified)
Apr 7, 2022
Pancreatic Cancer Trial in Tianjin (albumin-bound paclitaxel)
Recruiting
- Pancreatic Cancer
- albumin-bound paclitaxel
-
Tianjin, Tianjin, ChinaRui Liu
Sep 14, 2021
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Gastric Cancer Trial in Wuhan (Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1)
Recruiting
- Gastric Cancer
- Albumin-bound Paclitaxel plus S-1
- Oxaliplatin plus S-1
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 3, 2022
Head and Neck Squamous Cell Carcinoma Trial (Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
- (no location specified)
Dec 29, 2021
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Feb 6, 2022
Advanced Triple Negative Breast Cancer Trial in Fuzhou (Apatinib Mesylate, Albumin-Bound Paclitaxel)
Not yet recruiting
- Advanced Triple Negative Breast Cancer
- Apatinib Mesylate
- Albumin-Bound Paclitaxel
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Aug 18, 2021
Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)
Recruiting
- Angiosarcoma Metastatic
- Abraxane combined with liposomal doxorubicin
-
Guangzhou, Guangdong, ChinaXing Zhang
Nov 15, 2021
Untreated Metastatic Pancreatic Ductal Adenocarcinoma Trial in Scottsdale (Nivolumab, Albumin-bound paclitaxel, Paricalcitol)
Active, not recruiting
- Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Nivolumab
- +4 more
-
Scottsdale, ArizonaHonorHealth Research Institute
Feb 15, 2022
Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)
Recruiting
- Breast Cancer
- Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
-
Chengdu, Chengdu, Sichuan, China, ChinaWest China Hospital, Sichuan University
Sep 10, 2021
Pancreatic Cancer Trial in Tianjin (SHR-1020+albumin-bound paclitaxel)
Recruiting
- Pancreatic Cancer
- SHR-1020+albumin-bound paclitaxel
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
May 21, 2021
Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)
Not yet recruiting
- Second Line Treatment of Gastric Cancer
- Camrelizumab
- +2 more
- (no location specified)
Dec 20, 2022
Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Atlanta
Recruiting
- Advanced Pancreatic Adenocarcinoma
- +2 more
- Gemcitabine
- +3 more
-
Atlanta, Georgia
- +2 more
Feb 28, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +4 more
- BET Bromodomain Inhibitor ZEN-3694
- +3 more
- (no location specified)
Jun 28, 2022
Breast Cancer Trial in China (Albumin-bound paclitaxel combined with carboplatin, Epirubicin combined with docetaxel)
Recruiting
- Breast Cancer
- Albumin-bound paclitaxel combined with carboplatin
- Epirubicin combined with docetaxel
-
Harbin, Heilongjiang, China
- +6 more
Jul 18, 2021
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment Trial in Zhuhai (Tislelizumab, Low-dose radiotherapy)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Treatment
- Tislelizumab
- Low-dose radiotherapy
-
Zhuhai, Guangdong, ChinaFifth Affilliated Hospital of Sun Yat-sen University
Apr 22, 2022